IN.PACT AV access randomized trial: Japan cohort outcomes through 12 months.

IF 1.5 4区医学 Q3 HEMATOLOGY

Therapeutic Apheresis and Dialysis Pub Date : 2023-08-01 DOI:10.1111/1744-9987.13966

Hiroaki Haruguchi, Kotaro Suemitsu, Naoko Isogai, Masaaki Murakami, Masahiko Fujihara, Kazuhiro Iwadoh, Jeremiah Menk, Hiroko Ookubo, Tomonari Ogawa, Levester Kirksey, Sanjay Misra, Angelo Santos, Chad Laurich, Omran Abul-Khoudoud, Adie Friedman, Vincent Gallo, Ahmed Kamel Abdel Aal, Mel Sharafuddin, Sreekumar Madassery, David Dexter, Charles Joels, Syed Hussain, Sandeep Bagla, Jeffrey Hull, John Ross, Jeffrey Hoggard, Bret Wiechmann, Naveen Atray, Randy Cooper, Neghae Mawla, Fernando Kafie, Kotaro Suemitsu, Naoko Isogai, Masahiko Fujihara, Masaaki Murakami, Shohei Fuchinoue, Kazuhiro Iwadoh, Tomonari Ogawa, Andrew Holden, Kesaka Wickremesekera

{"title":"IN.PACT AV access randomized trial: Japan cohort outcomes through 12 months.","authors":"Hiroaki Haruguchi, Kotaro Suemitsu, Naoko Isogai, Masaaki Murakami, Masahiko Fujihara, Kazuhiro Iwadoh, Jeremiah Menk, Hiroko Ookubo, Tomonari Ogawa, Levester Kirksey, Sanjay Misra, Angelo Santos, Chad Laurich, Omran Abul-Khoudoud, Adie Friedman, Vincent Gallo, Ahmed Kamel Abdel Aal, Mel Sharafuddin, Sreekumar Madassery, David Dexter, Charles Joels, Syed Hussain, Sandeep Bagla, Jeffrey Hull, John Ross, Jeffrey Hoggard, Bret Wiechmann, Naveen Atray, Randy Cooper, Neghae Mawla, Fernando Kafie, Kotaro Suemitsu, Naoko Isogai, Masahiko Fujihara, Masaaki Murakami, Shohei Fuchinoue, Kazuhiro Iwadoh, Tomonari Ogawa, Andrew Holden, Kesaka Wickremesekera","doi":"10.1111/1744-9987.13966","DOIUrl":null,"url":null,"abstract":"Purpose: There is a lack of adjudicated and prospectively randomized published outcomes on the use of drug-coated balloons (DCB) to treat dysfunctional arteriovenous fistula in Asian patients. This post hoc subgroup analysis of 112 Japanese participants from the global IN.PACT AV Access trial reports outcomes through 12 months.Materials and methods: Participants were treated with DCB (n = 58) or standard non-coated percutaneous transluminal angioplasty (PTA) balloons (n = 54). Outcomes included target lesion primary patency (TLPP), access circuit primary patency, and safety.Results: Through 6 months, TLPP was 86.0% (49/57) in the DCB group and 49.1% (26/53) in the PTA group (p < 0.001). Through 12 months, TLPP was 67.3% (37/55) in the DCB group and 43.4% (23/53) in the PTA group (p = 0.013).Conclusion: In this post hoc analysis of Japanese participants from the IN.PACT AV Access trial, participants treated with DCB had higher TLPP through 6 and 12 months compared with PTA.","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.13966","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose: There is a lack of adjudicated and prospectively randomized published outcomes on the use of drug-coated balloons (DCB) to treat dysfunctional arteriovenous fistula in Asian patients. This post hoc subgroup analysis of 112 Japanese participants from the global IN.PACT AV Access trial reports outcomes through 12 months.

Materials and methods: Participants were treated with DCB (n = 58) or standard non-coated percutaneous transluminal angioplasty (PTA) balloons (n = 54). Outcomes included target lesion primary patency (TLPP), access circuit primary patency, and safety.

Results: Through 6 months, TLPP was 86.0% (49/57) in the DCB group and 49.1% (26/53) in the PTA group (p < 0.001). Through 12 months, TLPP was 67.3% (37/55) in the DCB group and 43.4% (23/53) in the PTA group (p = 0.013).

Conclusion: In this post hoc analysis of Japanese participants from the IN.PACT AV Access trial, participants treated with DCB had higher TLPP through 6 and 12 months compared with PTA.

查看原文本刊更多论文

在。PACT AV进入随机试验:日本队列12个月的结果

目的:在亚洲患者中，使用药物包被球囊(DCB)治疗功能障碍动静脉瘘缺乏经过裁决和前瞻性随机发表的结果。这是对112名来自全球IN的日本参与者的事后亚组分析。PACT AV Access试验报告为期12个月的结果。材料和方法:参与者接受DCB (n = 58)或标准无涂层经皮腔内血管成形术(PTA)球囊治疗(n = 54)。结果包括靶病变初级通畅(TLPP)、通路初级通畅和安全性。结果:6个月后，DCB组的TLPP为86.0% (49/57)，PTA组的TLPP为49.1%(26/53)。在PACT AV准入试验中，与PTA相比，DCB治疗的参与者在6个月和12个月的TLPP更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.